2 results match your criteria: "Anticancer Hospital of Thessaloniki Theageneio[Affiliation]"
The Effect of Early vs Delayed Initiation of Adalimumab on Remission Rates in Patients With Crohn's Disease With Poor Prognostic Factors: The MODIFY Study.
Crohns Colitis 360
October 2021
Department of Gastroenterology, General Hospital of Heraklion "Venizeleio-Pananeio", Heraklion, Crete, Greece.
Article Synopsis
- This study investigates the impact of early vs delayed treatment with adalimumab (ADL) on remission rates in Crohn's disease patients with poor prognostic factors, using data from 10 hospitals in Greece.
- Results showed that patients who started ADL within 24 months of diagnosis had a higher 26-week remission rate (60.7%) compared to those who started after 24 months (47.2%), particularly in those new to anti-tumor necrosis factor treatments.
- Overall, early treatment led to better clinical outcomes, with higher remission and response rates, especially for patients who were steroid-dependent or had additional health complications related to their condition.
Azathioprine-Induced Tremor: A Rare, Dose-Dependent Side Effect of Azathioprine in a Patient With Active Crohn Disease.
Inflamm Bowel Dis
June 2020
Gastroenterology Department, Anticancer Hospital of Thessaloniki Theageneio, Thessaloniki, Greece.